Professor, Neurosciences, UCSD School of Medicine
Neurology
Dr. Douglas R. Galasko, MD
|
|
Give Review
Douglas Galasko is an expert in the field of Neurology. Douglas Galasko is a published doctor as well. He has 55 publications published. The latest was: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. He is registered with Medicare and accepts Medicare payments.
Publications
- Pulse Pressure in Relation to Tau-Mediated Neurodegeneration, Cerebral Amyloidosis, and Progression to Dementia in Very Old Adults.
- Cerebrospinal fluid peptides as potential Parkinson Disease biomarkers: a staged pipeline for discovery and validation.
- Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease.
- Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study.
- Longitudinal plasma amyloid beta in Alzheimer's Disease clinical trials.
- Influence of lifestyle modifications on age-related free radical injury to Brain.
- Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.
- Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's Disease.
- Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's Disease.
- Advancing research diagnostic criteria for Alzheimer's Disease: the IWG-2 criteria.
- Targeted Discovery and Validation of Plasma Biomarkers of Parkinson's Disease.
- Alzheimer's Disease cooperative study prevention instrument project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study.
- Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates.
- Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.
- Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer Disease.
- Cross-Sectional and Longitudinal Relationships Between CerebroSpinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adu...
- TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.
- Widespread microRNA dysregulation in multiple system atrophy - Disease-related alteration in miR-96.
- The New Qualitative Scoring MMSE Pentagon Test (QSPT) as a Valid Screening Tool between Autopsy-Confirmed Dementia with Lewy Bodies and Alzheimer's Disease.
- Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults.
- Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's Disease.
- Association of cerebroSpinal fluid Aβ42 with A2M gene in cognitively normal subjects.
- Distinctive patterns of DNA methylation associated with Parkinson Disease: Identification of concordant epigenetic changes in brain and peripheral blood leukocytes.
- Accounting for functional loss in Alzheimer's Disease and dementia with Lewy bodies: Beyond cognition.
- Interrater reliability of the new criteria for behavioral variant frontotemporal Dementia.
- GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease.
- CerebroSpinal fluid norepinephrine and cognition in subjects across the adult age span.
- Biomarkers for Alzheimer's Disease in plasma, serum and blood - conceptual and practical problems.
- Neuropsychiatric Features of Frontal Lobe Dysfunction in Autopsy-Confirmed Patients with Lewy Bodies and "Pure" Alzheimer Disease.
- Walking stabilizes cognitive functioning in Alzheimer's Disease (AD) across one year.
- Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed Dementia with lewy bodies.
- Improved Statistical Power of Alzheimer Clinical Trials by Item-Response Theory: Proof of Concept by Application to the Activities of Daily Living Scale.
- Recent Alzheimer's Disease research highlights.
- Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's Diseases.
- Degree of bilingualism predicts age of diagnosis of Alzheimer's Disease in low-education but not in highly educated Hispanics.
- Modeling of pathological traits in Alzheimer's Disease based on systemic extracellular signaling proteome.
- Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's Disease.
- Fractional synthesis and clearance rates for amyloid ?.
- Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's Disease.
- CSF Aβ(42) and tau in Parkinson's Disease with cognitive impairment.
- YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's Disease.
- SNCA variant associated with Parkinson Disease and plasma alpha-synuclein level.
- The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.
- Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer Disease cerebrospinal fluid.
- Cerebrospinal fluid concentration of Brain-derived neurotrophic factor and cognitive function in non-demented subjects.
- Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
- Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.
- Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's Disease or prog...
- Age and apolipoprotein E*4 allele effects on cerebroSpinal fluid beta-amyloid 42 in adults with normal cognition.
- Temporal sequence learning in healthy aging and amnestic mild cognitive impairment.
- Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's Disease.
- Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease.
- Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.
Schools
University Of The Witwatersrand Faculty Of Health Sciences
Boston University Med CtrUniv Hp
Johns Hopkins Hospital
Conditions Treated
- Alzheimer's Disease
- Bell's Palsy
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
Johns Hopkins University -
Boston University Medical Center -
University of the Witwatersrand
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1336197730 | |
| NPPES Provider LastName | GALASKO | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 920371300 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 530.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336197730 |
| Last Name Of The Provider | GALASKO |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. John S. Romine, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dee E. Silver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Rafii, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart A. Lipton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. J S. Poceta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maung H. Aung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David E. Piccioni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abraham S. Chyung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kulreet K. Chaudhary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick J. De La Vega, MD |